Lexipafant(BB-882), a potent PAF antagonist in acute pancreatitis

Advances in Experimental Medicine and Biology

Volumn 416, Issue , 1997, Pages 361-363

  Curtis, Lloyd D ^a  

^a British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LEXIPAFANT; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

ACUTE PANCREATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0030937894     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (16)

1. Fernandez-del Castillo C, Rattner DW, Warshaw AL. Acute Pancreatitis. Lancet 1993;342:475-479.
2. Bradley EL. A Clinically based classification system for acute pancreatitis, summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg 1993;128:586-590.
3. Larvin M, McMahon MJ. Apache-11 score for assessment and monitoring of acute pancreatitis. Lancet 1989; :201-205.
4. Heath D, Alexander D, Wilson C, Larvin M, Imrie CW, McMahon. Which complications of acute pancreatitis are most lethal? A prospective multi-centre study of 719 attacks. Gut 1995; 36:3, A478.
5. McFadden D.W. Organ failure and multiple organ system failure in pancreatitis. Pancreas 1991:6, Suppl.1:S37-S43.
6. Buchler M, Malfertheiner P, Uhl W, et al. Gabexate mesilate in human acute pancreatitis. Gastroenterology 1992;104:1165-1170.
7. Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O'Neill J, Blumgart LH. A single-centre double blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg 1978;65:337-341.
8. Bone RC, Balk RA, Cerra FB et al. ACCP/SCCM consensus conference: definitions for Sepsis and Organ failure and Guidelines for the Use of Innovative Therapies in Sepsis. Chest 1992;101:1644-1655.
9. Konturek SJ, Dembinski A, Konturek PJ, Warzecha Z, Jaworek J, Grustaw P, R Tomasxewska R, Stachura J. Role of platelet activating factor in pathogenesis of acute pancreatitis in rats. Gut 1992;33:1268-1274.
10. Emanuelli G, Montrucchio G, Gaia E, Gughera L, Corvetti G, Gurbetta L. Experimental acute pancreatitis induced by platelet activating factor in rabbits. Am J Path 1989;134:315-326.
11. Zhou W, McOllum MO, Levine BA, Olson MS. Role of platelet activating factor in pancreatitis-associated lung injury in the rat. Am J Path 1992;140:971-979.
12. Guillermo A, Lopez Farre A, Gomez Garre DN, Novo C, Romeo JM, Branquet P, Lopez-Novoa JM. Role of platelet activating factor in haemodynamic derangements in an acute rodent pancreatic model. Gastroenterology 1992;102:181-187.
13. Chank SW, Fedderson CO, Henson PM, Voelkel NF. Platelet activating factor mediates haemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 1987;79:1498-1509.
14. Formela LJ, Wood LM, Whittaker M, Kingsnorth AN. Amelioration of experimental acute pancreatitis with a potent platelet-activating factor antagonist. Br J Surg 1994;81:1783-1785.
15. Galloway SW, Kingsnorth AN. Lung injury in the microembolic model of acute pancreatitis and amelioration by a platelet-activating factor antagonist. Pancreas 1995. In press.
16. Kingsorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase II trial of lexipafant, a platelet-activating factor antagonist in human pancreatitis. British J of Surg 1995. In Press.